$OGI

OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates

OrganiGram (OGI) reported Q3 adjusted EPS loss of $0.05 per share, wider than the Zacks Consensus loss of $0.01, while revenue rose to $76.41 million, 12.95% above estimates. Year-ago revenue was $51.16 million. The article cites a Zacks Rank #3 (Hold) and notes consensus outlook of $0.01 EPS on $79.35 million revenue next quarter.

Original reporting
Published Aug 11, 2026, 1:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 5:20 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$OGI
Neutral
medium confidence
Mentioned
$OGI
Relevance
6/10
alphai data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$OGINeutralMed
01

Why it matters

For trading, the key decision point is whether management’s commentary supports the revenue strength with improving profitability and whether near-term consensus estimates move after the call.

02

Market read

This is a single-company earnings datapoint with a clear EPS miss and revenue beat, making the earnings call commentary the main catalyst for follow-through.

03

What to watch

The article does not detail cash flow, gross margin, or guidance changes; traders should focus on those items in the earnings call to judge whether the EPS miss is structural or one-off.

Relevance 6/10Novelty 6/10Timing: post-Q3 release, ahead of management commentary on the earnings call

Background

The article frames OrganiGram’s Q3 as an earnings surprise on EPS (adjusted) while highlighting a revenue beat and a mixed recent estimate-revision trend.

Company-level read

Ticker impact

$OGINeutralMedium confidence
Context

OrganiGram reported Q3 adjusted EPS of -$0.05 versus -$0.01 consensus and revenues of $76.41M, beating estimates by 12.95%.

Expected impact

Near-term volatility likely hinges on management commentary, since the article flags that immediate price movement depends on the earnings call.

Evidence & confidence

The article provides the core datapoints (EPS miss, revenue beat, and consensus outlook figures) but does not include guidance or qualitative drivers beyond pointing to the upcoming earnings call.

Market effects

Cannabis producers with similar earnings profiles may see read-across trading based on whether revenue growth can offset profitability pressure.

No specific regional spillover described.

No global macro or cross-border catalyst described.

Counterpoint

Revenue beat could indicate improving top-line momentum, so the EPS miss may be temporary if costs normalize in subsequent quarters.

Key entities

  • OrganiGram

    Reported Q3 adjusted EPS of -$0.05 and revenues of $76.41M, with EPS missing consensus and revenue beating consensus.

  • Zacks Consensus Estimate

    The article’s reference point for EPS (-$0.01) and revenue ($76.41M beat by 12.95%).

  • Zacks Rank

    The article cites a Zacks Rank #3 (Hold) ahead of the earnings release.

Related articles

$OGIMed

Organigram Global Inc.: Organigram Global Accelerates Integration of Sanity Group Under Unified Global Operating Structure

Organigram Global Inc. (OGI) accelerated the integration of Sanity Group, aligning leadership and operations. Sanity contributed CAD 40 million (35% of revenue) in the last quarter, with revenue growing 34% to €25.5 million. The company amended the earnout agreement, fixing it at 85% of the maximum value, with €20 million in cash and €76 million in shares payable in 2027. New leadership roles were appointed to support global growth.

$OGIMedAI 8/10

Organigram (OGI) Q3 2026 Earnings Call Transcript

Organigram (OGI) reported Q3 2026 revenue of $105.8M, up 49% YoY, driven by Sanity Group acquisition. Adjusted EBITDA rose 136% to $13.4M. International sales now 35% of total revenue. CEO Yamanaka highlighted strategic transformation and record THC potency. CFO Guyatt expects margins to exceed fiscal 2025 levels. The company faces EU supply constraints and U.S. regulatory uncertainty.

$OGIMed

Organigram Global Inc. Q3 2026 Earnings Call Summary

Organigram Global Inc. reported Q3 2026 record net revenue and adjusted EBITDA, citing Sanity Group’s first consolidation and Canada operational efficiencies. International revenue rose to about 35% of total. It reiterated FY2026 revenue guidance above $350 million and expects Q4 positive free cash flow. Net income was $105.5 million, including $105.8 million fair value gains.